FDA commissioner stirs debate over hormone therapy for menopause
The 12-person panel encouraged the use of the treatment late last week and called for the removal of the Food and Drug Administration's 'black box' warning label on hormone treatments.
'I am begging the FDA, and all of us are begging, please remove the black box label,' said JoAnn Pinkerton, a panelist and professor of obstetrics and gynecology and division direct of midlife health at the University of Virginia Health System. She specifically referred to low-dose vaginal estrogen therapies. 'Please stop harming women.'
Women's health experts have long had mixed thoughts on menopause hormone therapy, with some arguing that the side effects outlined in the Women's Health Initiative were overblown while others still believe the treatment poses serious long-term health risks.
'Menopausal hormone therapy is effective for vasomotor symptoms and vaginal dryness, but those are the only proven symptomatic benefits,' Adriane Fugh-Berman, a professor of pharmacology at Georgetown University Medical Center, and Barbara Mintzes, a professor of pharmaceutical policy at the University of Sydney wrote in an editorial about the panel.
'Serious harms, including stroke, pulmonary embolism, gallbladder disease, and increased breast cancer risk are trivialized or ignored in current narratives.'
Many health care providers stopped prescribing hormone therapy to treat menopause symptoms after a large long-term study called the Women's Health Initiative (WHI) came out in 2002.
The randomized controlled trial, looked at the impacts of estrogen use to treat menopause symptoms on more than 10,000 women in the 1990s and the impacts of using both estrogen and a progestin hormone on more than 16,000 women.
Both arms of the study were stopped when researchers found that the estrogen-progestin regimen increased the risk of invasive breast cancer, pulmonary embolism and stroke, while estrogen-only increased the risk of stroke.
Since then, treatments for the condition that include estrogen come with a boxed warning stating that they come with an increased risk for stroke, deep vein thrombosis and dementia. Labels also state that estrogen and estrogen plus progestin therapy should not be used to treat cardiovascular disease or dementia.
One of the issues with the study is that it examined the impacts of hormone therapy on women who were, on average, 63 years old, which is roughly a decade older than most women are when they start menopause, according to proponents of the treatment.
Proponents, like Pinkerton, stress that it is beneficial to women if they start before age 60, or within 10 years of staring menopause.
Other issues supporters point to are that the study only looked at one type of oral hormone therapy, and it examined the consequences of using synthetic progesterone, since natural progesterone was not approved by the FDA well after the study was conducted, according to Elizabeth Poyner, head of the Atria Health and Research Institute.
'Synthetic progestins we know are associated with an elevated risk of breast cancer,' she said. 'They are associated with an elevated risk of breast cancer in birth control pills, maybe even with IUDs, but certainly in hormone replacement therapy.'
Some authors of the WHI published a review in JAMA last May stating that there are benefits to menopausal hormone therapy for some women.
In the review, researchers note that hormone therapy is effective for treating some 'moderate to severe' early menopause symptoms like hot flashes and night sweats. Those benefits support the 'initiation of hormone therapy before age 60 years for women without contraindications to hormone therapy.'
The FDA panel was filled with supporters for menopause hormone therapy who emphasized observational studies.
Some women's health advocates critical of the treatment sat in the audience of last week's panel, according to The New York Times. When asked by an audience member if there would be time for public comment, FDA Commissioner Marty Makary said that comments took time, and he wanted to act quickly, the outlet added.
Makary has had a special interest in menopause hormone therapy, which he mentions in his book 'Blind Spots' as an example of how conventional thinking in health care is hurting Americans.
Makary did not say if the FDA planned to change the boxed warning on menopause hormone therapies. A spokesperson for the Department of Health and Human Services, which oversees the FDA, declined to comment on any future changes to the treatment's labeling.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
10 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
11 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
Wall Street Journal
12 hours ago
- Wall Street Journal
Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health.
